Novavax (NVAX) Reports Q3 Loss of $3.21/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novavax Reports Third Quarter 2020 Financial and Operational Results
November 9, 2020 4:06 PM ESTAdvanced clinical development of NVXCoV2373 with initiation of first Phase 3 trial to evaluate efficacy, safety and immunogenicityU.K. Phase 3 interim data expected as soon as early first quarter 2021Secured additional large-scale manufacturing for NVX-CoV2373 with expected global capacity over two billion doses by mid-2021Formed leadership team to advance NanoFlu through global licensureCompany to host conference call today at 4:30 p.m. ET
GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for... More
